A trial looking at chemotherapy after surgery to remove cancer of the pancreas (ESPAC-4)

This trial compared gemcitabine on its own with gemcitabine alongside capecitabine after surgery for cancer of the pancreas.

There are 2 parts to this trial. Part 1 was for people with the most common type of pancreatic cancer. This is called ductal adenocarcinoma cancer of the pancreas. This part of the trial is now closed and the trial team published these results in 2017. The results are summarised in the trial result section below.

Part 2 is closed to recruitment. It is looking at people with cancer where the pancreatic duct meets the bile duct, the ampulla of Vater. This is called ampullary cancer. We have a summary of this on our trials database.

Cancer Research UK supports this trial.